Christine M Heske1, Yueh-Yun Chi2, Rajkumar Venkatramani3, Minjie Li4, Michael A Arnold5,6, Roshni Dasgupta7, Susan M Hiniker8, Douglas S Hawkins9, Leo Mascarenhas10. 1. Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2. Department of Pediatrics and Preventative Medicine, University of Southern California, Los Angeles, California. 3. Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. 4. Department of Biostatistics, College of Public Health and Health Professions College of Medicine, University of Florida, Gainesville, Florida. 5. Department of Pathology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado. 6. Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, Colorado. 7. Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. 8. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. 9. Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington. 10. Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Division of Hematology/Oncology, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND: The objective of this analysis was to evaluate the clinical factors influencing survival outcomes in patients with localized (clinical group I-III), FOXO1 fusion-positive rhabdomyosarcoma (RMS). METHODS: Patients with confirmed FOXO1 fusion-positive RMS who were enrolled on 3 completed clinical trials for localized RMS were included in the analytic cohort. Outcomes were analyzed using the Kaplan-Meier method to estimate event-free survival (EFS) and overall survival (OS), and the curves were compared using the log-rank test. A Cox proportional hazards regression model was used to perform multivariate analysis of prognostic factors that were significant in the univariate analysis. RESULTS: The estimated 4-year EFS and OS of 269 patients with localized, FOXO1 fusion-positive RMS was 53% (95% CI, 47%-59%) and 69% (95% CI, 63%-74%), respectively. Univariate analysis revealed that several known favorable clinical characteristics, including age at diagnosis between 1 and 9 years, complete surgical resection, tumor size ≤5 cm, favorable tumor site, absence of lymph node involvement, confinement to the anatomic site of origin, and PAX7-FOXO1 fusion, were associated with improved outcomes. Multivariate analysis identified older age (≥10 years) and large tumor size (>5 cm) as independent, adverse prognostic factors for EFS within this population, and patients who had both adverse features experienced substantially inferior outcomes. CONCLUSIONS: Patients with localized, FOXO1 fusion-positive RMS can be further risk stratified based on clinical features at diagnosis, and older patients with large primary tumors have the poorest prognosis.
BACKGROUND: The objective of this analysis was to evaluate the clinical factors influencing survival outcomes in patients with localized (clinical group I-III), FOXO1 fusion-positive rhabdomyosarcoma (RMS). METHODS: Patients with confirmed FOXO1 fusion-positive RMS who were enrolled on 3 completed clinical trials for localized RMS were included in the analytic cohort. Outcomes were analyzed using the Kaplan-Meier method to estimate event-free survival (EFS) and overall survival (OS), and the curves were compared using the log-rank test. A Cox proportional hazards regression model was used to perform multivariate analysis of prognostic factors that were significant in the univariate analysis. RESULTS: The estimated 4-year EFS and OS of 269 patients with localized, FOXO1 fusion-positive RMS was 53% (95% CI, 47%-59%) and 69% (95% CI, 63%-74%), respectively. Univariate analysis revealed that several known favorable clinical characteristics, including age at diagnosis between 1 and 9 years, complete surgical resection, tumor size ≤5 cm, favorable tumor site, absence of lymph node involvement, confinement to the anatomic site of origin, and PAX7-FOXO1 fusion, were associated with improved outcomes. Multivariate analysis identified older age (≥10 years) and large tumor size (>5 cm) as independent, adverse prognostic factors for EFS within this population, and patients who had both adverse features experienced substantially inferior outcomes. CONCLUSIONS: Patients with localized, FOXO1 fusion-positive RMS can be further risk stratified based on clinical features at diagnosis, and older patients with large primary tumors have the poorest prognosis.
Authors: Douglas S Hawkins; Yueh-Yun Chi; James R Anderson; Jing Tian; Carola A S Arndt; Lisa Bomgaars; Sarah S Donaldson; Andrea Hayes-Jordan; Leo Mascarenhas; Mary Beth McCarville; Jeannine S McCune; Geoff McCowage; Lynn Million; Carol D Morris; David M Parham; David A Rodeberg; Erin R Rudzinski; Margarett Shnorhavorian; Sheri L Spunt; Stephen X Skapek; Lisa A Teot; Suzanne Wolden; Torunn I Yock; William H Meyer Journal: J Clin Oncol Date: 2018-08-09 Impact factor: 44.544
Authors: Frederic G Barr; Lynette M Smith; James C Lynch; Donna Strzelecki; David M Parham; Stephen J Qualman; Philip P Breitfeld Journal: J Mol Diagn Date: 2006-05 Impact factor: 5.568
Authors: David O Walterhouse; Jane L Meza; John C Breneman; Sarah S Donaldson; Andrea Hayes-Jordan; Alberto S Pappo; Carola Arndt; R Beverly Raney; William H Meyer; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2011-02-04 Impact factor: 3.167
Authors: Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2013-03-22 Impact factor: 3.167
Authors: N Galili; R J Davis; W J Fredericks; S Mukhopadhyay; F J Rauscher; B S Emanuel; G Rovera; F G Barr Journal: Nat Genet Date: 1993-11 Impact factor: 38.330
Authors: Erin R Rudzinski; Lisa A Teot; James R Anderson; Julie Moore; Julia A Bridge; Frederic G Barr; Julie M Gastier-Foster; Stephen X Skapek; Douglas S Hawkins; David M Parham Journal: Am J Clin Pathol Date: 2013-07 Impact factor: 2.493
Authors: Emily Hibbitts; Yueh-Yun Chi; Douglas S Hawkins; Frederic G Barr; Julie A Bradley; Roshni Dasgupta; William H Meyer; David A Rodeberg; Erin R Rudzinski; Sheri L Spunt; Stephen X Skapek; Suzanne L Wolden; Carola A S Arndt Journal: Cancer Med Date: 2019-08-27 Impact factor: 4.452
Authors: Josephine H Haduong; Christine M Heske; Wendy Allen-Rhoades; Wei Xue; Lisa A Teot; David A Rodeberg; Sarah S Donaldson; Aaron Weiss; Douglas S Hawkins; Rajkumar Venkatramani Journal: Pediatr Blood Cancer Date: 2022-02-07 Impact factor: 3.167
Authors: Yun Wei; Qian Qin; Chuan Yan; Madeline N Hayes; Sara P Garcia; Haibin Xi; Daniel Do; Alexander H Jin; Tiffany C Eng; Karin M McCarthy; Abhinav Adhikari; Maristela L Onozato; Dimitrios Spentzos; Gunnlaugur P Neilsen; A John Iafrate; Leonard H Wexler; April D Pyle; Mario L Suvà; Filemon Dela Cruz; Luca Pinello; David M Langenau Journal: Nat Cancer Date: 2022-08-18
Authors: Mrinal M Gounder; Narasimhan P Agaram; Sally E Trabucco; Victoria Robinson; Richard A Ferraro; Sherri Z Millis; Anita Krishnan; Jessica Lee; Steven Attia; Wassim Abida; Alexander Drilon; Ping Chi; Sandra P D' Angelo; Mark A Dickson; Mary Lou Keohan; Ciara M Kelly; Mark Agulnik; Sant P Chawla; Edwin Choy; Rashmi Chugh; Christian F Meyer; Parvathi A Myer; Jessica L Moore; Ross A Okimoto; Raphael E Pollock; Vinod Ravi; Arun S Singh; Neeta Somaiah; Andrew J Wagner; John H Healey; Garrett M Frampton; Jeffrey M Venstrom; Jeffrey S Ross; Marc Ladanyi; Samuel Singer; Murray F Brennan; Gary K Schwartz; Alexander J Lazar; David M Thomas; Robert G Maki; William D Tap; Siraj M Ali; Dexter X Jin Journal: Nat Commun Date: 2022-06-15 Impact factor: 17.694